Background: The role of second-line chemotherapy in advanced gastric cancer is not yet fully established. Patients and Methods: We analysed 111 patients with advanced gastric cancer treated at the University Hospital Heidelberg (51) and the private oncology practice Bottrop/Dorsten (60) between 2001 and 2011, comparing the outcome of patients with first-line chemotherapy and those who received second-line chemotherapy. Results: Thirty-six patients were treated with one chemotherapy regimen, 75 patients received at least two different chemotherapies. Patients who received one chemotherapy regimen were older (median age 69 years) and had a shorter overall survival (6 months) than patients receiving sequential chemotherapies [median age 61 years, p = 0.009, overall survival 14 months (2-42), p = 0.001]. Under second-line chemotherapy, partial response was observed in 25 patients (33%) and stable disease for ≥3 months in 26 patients (35%). Patients treated before 2005 had a slightly better overall survival than patients treated in or after 2005. Survival was not influenced by the treatment centre (primary or tertiary), but was influenced by former surgery. Conclusion: The prognosis of advanced gastric cancer is still poor. Selected patients may benefit from individualized salvage chemotherapy after failure of first-line chemotherapy.

Keywords:
Gastric cancer, Second-line chemotherapy
1.
Scheithauer W, Kornek G, Zeh B: Palliative chemotherapy versus best supportive care in patients with metastatic gastric cancer: a randomized trial. Köln, Second International Conference on Biology, Prevention and Treatment of GI Malignancies, 1995, p 68.
2.
Murad AM, Santiago FF, Petroianu A, Rocha P, Rodrigues M, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
3.
Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Brit J Cancer 1995;71:587-591.
4.
Glimelius B, Ekström K, Hoffmann K, Graf W, Sjöden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellström H, Heumann R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-168.
5.
Stahl M, Muller C, Koster W, Wilke H: Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy. Onkologie 2005;28:499-502.
6.
Wilson D, Hiller L, Geh JI: Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol 2005;17:81-90.
7.
Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, Hill ME, Normann AR: Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004;15:64-69.
8.
Schmidt KE, Kornek GV, Schüll B, Raderer M, Lenauer A, Depisch D, Lange F, Scheithauer W: Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed Onkologie 2003;26:255-258.
9.
Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P: Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:2306-2314.
10.
Kang JH, Lee SI, Lim do H, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH: Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30:1513-1518.
11.
Kelley JR, Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1-9.
12.
Roth AD: Chemotherapy in gastric cancer: a never ending saga. Ann Oncol 2003;14:175-177.
13.
Schulze-Bergkamen H, Zuna I, Teufel A, Stremmel W, Rudi J: Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting: efficacy of therapy and value of serum tumor markers. Med Oncol 2002;19:43-53.
14.
Park JS, Lim JY, Park SK, Kim MK, Ko HS, Yoon SO, Kim JW, Choi SH, Cho JY: Prognostic factors of second and third line chemotherapy using 5-FU with platinum, irinotecan, and taxane for advanced gastric cancer. Cancer Res Treat 2011;43:236-243.
15.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
16.
Vanhoefer U, Wagener T, Lutz M, Van Cutsem E, Nordlinger B, Reuse S, Baron B, Wilke H, Wils J: Randomized phase II study of weekly 24h infusion of high dose 5-FU +/- folinic acid (HD-FU +/- FA) vs. HD-FU/FA/biweekly cisplatin in advanced gastric cancer. Eur J Cancer 2001;37(suppl 6):S27.
17.
Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-267.
18.
Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004.
19.
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997.
20.
Al-Batran S, Stöhlmacher J, Probst S, Hollerbach S, Wilhelm G, Derigs H, Seipelt G, Kojouharoff G, Graubner M, Hinke A, Jäger E: Fluourouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) as a first-line therapy for patients with advanced gastric cancer; first interim analysis of a randomised multicenter phase II study. J Clin Oncol 2005;23:S311.
21.
Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsene D, Paitel JF, Guerin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C: Randomized multicenter phase II trial of biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803. J Clin Oncol 2004;22:4319-4328.
22.
Moehler M, Eimermacher A, Siebler J, Hohler T, Wein A, Menges M, Flieger D, Junginger T, Geer T, Gracien E, Galle PR, Heike M: Randomized phase II evaluation of irinotecan plus high-dose 5-fluourouracil and leucovorin (IFL) versus 5-fluourouracil, leucovorin and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005;92:2122-2128.
23.
Dank M, Zaluski J, Barone C, Valvere V, Peschel C, Wenczl M, Goker E, Risse M, Awad L, Bugat R: Randomized phase III trial of irinotecan (CPT 11) - 5-FU/folinic acid (FA) vs. CDDP + 5-FU in first line advanced gastric cancer patients. J Clin Oncol 2005;23:S308.
24.
Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-2909.
25.
Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluourouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
26.
Hashimoto K, Takashima A, Nagashima K, Okazaki SS, Nakajima TE, Kato K, Hamaguchi T, Yamada Y, Shimada Y: Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. J Cancer Res Clin Oncol 2010;136:1059-1064.
27.
Bohanes P, Courvoisier DS, Perneger TV, Morel P, Huber O, Roth AD: Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer. Swiss Med Wkly 2011;141:w13249.
28.
Catalano V, Graziano F, Santini D, D‘Emidio S, Baldelli AM, Rossi D, Vincenzi B, Giordani P, Alessandroni P, Testa E, Tonini G, Catalano G: Second line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer 2008;99:1402-1407.
29.
Kanagavel D, Pokataev IA, Fedyanin MY, Tryakin AA, Bazin IS, Narimanov MN, Yakovleva ES, Garin AM, Tjulandin SA: A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol 2010;21:1779-1785.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.